E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
- Relapsing multiple sclerosis (RMS)/Primary Progressive Multiple Sclerosis (PPMS)
|
|
E.1.1.1 | Medical condition in easily understood language |
RMS is the most common form of MS which causes inflammation of insulating membranes(myelin)that surround nerves. PPMS is characterized by continuous progression of disability independent from relapses |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10028245 |
E.1.2 | Term | Multiple sclerosis |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10063399 |
E.1.2 | Term | Relapsing-remitting multiple sclerosis |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10063401 |
E.1.2 | Term | Primary progressive multiple sclerosis |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To understand the impact of ocrelizumab treatment on neurofilament light (NfL) as a biomarker of neuronal damage in cerebrospinal fluid (CSF)
• To assess the number of cluster of differentiation (CD)19+ B cells in CSF (cell number/microliter) before and after treatment with ocrelizumab
• To assess the number of CD3+ T cells in CSF (cell number/microliter) before and after treatment with ocrelizumab |
|
E.2.2 | Secondary objectives of the trial |
• The safety objective for this study, including for the Long-Term Extension, is to evaluate the safety of ocrelizumab |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
General Inclusion Criteria
- Age 18 − 55 years, inclusive
- For women of childbearing potential: agreement to remain abstinent
(refrain from heterosexual intercourse) or use contraceptive methods
that result in a failure rate of < 1% per year during the treatment period
and for at least 24 weeks after the last dose of study treatment or until
their B cells have repleted, whichever is longer
Inclusion Criteria Specific to RMS Patients
- Diagnosis of RMS in accordance with the 2010 revised McDonald criteria
- Expanded Disability Status Scale (EDSS) score of 0 − 5.5 points, inclusive, at screening
- Disease duration less than 15 years in participants with an EDSS > 5.0 at screening
- Either treatment-naive or receiving treatment with disease-modifying therapies, including prior use of IFN-beta-1a (Avonex®, Rebif®), IFN-beta-1b (Betaseron®/Betaferon), or glatiramer acetate (Copaxone®)
- At least one clinically documented relapse in the past year and/or at least one T1-weighted Gd-enhancing lesion in the past year and/or at least one new T2 lesion in the past year at the time of enrollment
Inclusion Criteria Specific to RMS Cohort Arm 4
- Must meet inclusion criteria for the RMS cohort
- Separate signed Informed Consent Form for the RMS Delayed Time to
Start Control Arm (Arm 4)
- Must be willing to remain on the same dose and regimen of current
standard of care, or no treatment if treatment-naïve, for 12 weeks after
study enrollment
Inclusion Criteria Specific to primary progressive multiple sclerosis
(PPMS) Patients
- Diagnosis of PPMS in accordance with the 2010 revised McDonald
criteria
- EDSS score of 3.0 − 6.5 points, inclusive, at screening
- Disease duration from the onset of MS symptoms: Less than 10 years
in patients with an EDSS at screening ≤ 5.0
- Documented history of at least one of the following laboratory findings
in CSF:
Elevated IgG Index
One or more IgG OCBs detected by isoelectric focusing |
|
E.4 | Principal exclusion criteria |
General Exclusion Criteria
- Diagnosis of primary progressive MS
- Diagnosis of secondary progressive MS (without relapses for at least 1 year)
- History or known presence of recurrent or chronic infection
- History of recurrent aspiration pneumonia requiring antibiotic therapy
- History of cancer
- History of or currently active primary or secondary immunodeficiency
- History of coagulation disorders
- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
- History of alcohol or other drug abuse within 24 weeks prior to enrollment
- Known presence or history of other neurologic disorders
- Significant, uncontrolled disease, such as cardiovascular, pulmonary, renal, hepatic, endocrine, gastrointestinal, or any other significant disease
- Congestive heart failure
- Known active bacterial, viral, fungal, mycobacterial infection, or other infection or any major episode of infection
- Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants
- Contraindications for, or intolerance to, oral or intravenous (IV) corticosteroids,
- Contraindication for lumbar puncture (LP)
- Previous treatment with B cell-targeted therapies
- Previous treatment with natalizumab (Tysabri®), alemtuzumab, anti-CD4 agents, cladribine, teriflunomide, cyclophosphamide, mitoxantrone, azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, total body irradiation, or bone marrow transplantation
- Treatment with fingolimod/Gilenya®, dimethyl fumarate/Tecfidera®, or similar treatment within 6 months prior to enrollment
- Receipt of live vaccine
- Systemic corticosteroid therapy within 4 weeks prior to baseline
- Previous or concurrent treatment with any investigational agent or treatment with any experimental procedure for MS
- Laboratory abnormalities or findings at screening
- Inability to complete Magnetic Resonance Image (MRI)
- Lack of peripheral venous access
Exclusion Criteria Specific to RMS Patients
- Diagnosis of PPMS or SPMS without relapses |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Change in levels of NfL in CSF from treatment baseline to post-treatment with ocrelizumab
2. Change in number of CD19+ B cells in CSF from treatment baseline to post-treatment with ocrelizumab
3. Change in number of CD3+ T cells in CSF from treatment baseline to post-treatment with ocrelizumab
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1-3. Treatment baseline (Day 1) and Weeks 12, 24, and 52 |
|
E.5.2 | Secondary end point(s) |
1. Changes in vital signs, physical findings and laboratory results
2. Incidence of AEs
3. AEs related to biomarker sample collection |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Explore the mechanism of action of ocrelizumab and B-cell biology
Biomarker study |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 5 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
United States |
Germany |
Sweden |
Switzerland |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The total length of the study is expected to be approximately 2.5 years
from the first patient enrolled to LPLV, excluding any follow-up.
Patients may be consented for participation in an OLE phase if, in the
opinion of the investigator, they may benefit from treatment with
ocrelizumab. The OLE phase would continue until the Sponsor decides
to terminate the ocrelizumab program. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 15 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |